IPP Bureau
Novartis Scemblix shows better result for chronic myeloid leukemia trial
By IPP Bureau - June 08, 2022
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
IOL Chemicals and Pharmaceuticals Q4 FY2022 PAT drops to Rs. 27.75 Cr
By IPP Bureau - June 08, 2022
The company has posted net profit of Rs.165.66 crores for the Financial Year ended March 31, 2022
Agilent to improve analysis speeds of genomics bioinformatics
By IPP Bureau - June 08, 2022
Cloud-native Alissa data analysis SaaS platform empowers clinical labs and researchers to scale operations with parallel analysis of genomic data
Future Packaging to redefine India Pharm industry growth: InnoPack Pharma
By IPP Bureau - June 07, 2022
The Innopack confex is a perfect platform for exhibitors to demonstrate their latest developments in the fields of pharmaceutical packaging, labelling, drug delivery device design and engineering.
Zydus Lifesciences receives USFDA approval for Adapalene and Benzoyl Peroxide Topical Gel
By IPP Bureau - June 07, 2022
The drug will be manufactured at the group’s topical facility at Ahmedabad
Thermo Fisher Scientific collaborates with TransMIT to promote MSI platform
By IPP Bureau - June 07, 2022
Co-marketing agreement between Thermo Fisher Scientific and TransMIT allows for high spatial and high mass resolution MSI platform to study complex biological tissues
Gufic Biosciences to grab a major share of Rs. 3,000 crore lyophilized antibacterial market
By IPP Bureau - June 07, 2022
The company has launched indigenously produced Dual Chamber Bags of global standards in India at a pocket-friendly price
NewAmsterdam Pharma shares new data from Phase 2b ROSE Study
By IPP Bureau - June 07, 2022
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
MEI Pharma and Kyowa Kirin report new clinical data on Zandelisib
By IPP Bureau - June 07, 2022
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
PM-JAY public dashboard gets revamped with new features
By IPP Bureau - June 07, 2022
The dashboard will serve as a single source of truth for public and PM-JAY stakeholders providing comprehensive view of scheme’s progress
Lonza launches new non-endotoxin pyrogen detection system
By IPP Bureau - June 07, 2022
The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics
Proxygen and Merck collaborates to develop molecular glue degraders
By IPP Bureau - June 06, 2022
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
FDA publishes ANP’s polymeric drug excipient DMF
By IPP Bureau - June 06, 2022
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
ANI Pharmaceuticals consolidates operation post Novitium acquisition
By IPP Bureau - June 06, 2022
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
APhA appoints Ilisa Bernstein Interim CEO
By IPP Bureau - June 06, 2022
Dr. Bernstein will tap into her decades of leadership and strategy experience as she transitions into this new role at APhA
